Genenta Science SpA (GNTA): חוב להון עצמי

Leveraging the powerful human capital of Milanese researchers, Genenta Science S.p.A. (GNTA) is developing advanced cancer treatments. This chart illustrating the historical change in the total debt-to-equity ratio is 0.38. The business is based on exclusive patents for brain tumor therapy, which guarantee stable profits. A high barrier to entry is ensured by complex laboratory infrastructure and strict safety controls for viral vectors.

The leverage ratio determines the proportion of borrowed obligations within the equity structure, measuring financial leverage and the business's level of dependence on external financing. By analyzing the current total debt-to-equity ratio, an investor assesses the stability of Genenta Science S.p.A. (GNTA), whose innovations in tumor gene therapy require a balance between debt load and equity to develop its unique gene delivery platform.